Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.58 |
| ▸ | HTR2C | P28335 | 8/20 | 0.58 |
| ▸ | HTR2B | P41595 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6798090 | 0.99 | HTR7 (0.57) | HTR7HTR2CHTR2BSMN1; SMN2ALDH1A1 | |
| SCHEMBL6800444 | 0.91 | HTR2C (0.57) | HTR7HTR2CHTR2BSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6807636 | 0.90 | HTR2C (0.56) | HTR7HTR2CHTR2BSMN1; SMN2ALDH1A1 | |
| SCHEMBL1242907 | 0.88 | HTR7 (0.65) | HTR7HTR2CHTR2BSMN1; SMN2ALDH1A1 | |
| SCHEMBL6801333 | 0.85 | HTR2C (0.55) | HTR7HTR2CHTR2BALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL6798790 | 0.84 | HTR2C (0.54) | HTR7HTR2CHTR2BALDH1A1ALOX15 | |
| SCHEMBL7848464 | 0.83 | HTR2C (0.70) | HTR2CHTR2BSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6802404 | 0.81 | SMN1; SMN2 (0.56) | HTR7SMN1; SMN2ALDH1A1TSHRLMNA | |
| SCHEMBL24069077 | 0.80 | HTR7 (0.87) | HTR7HTR2CSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17258825 | 0.79 | PNMT (0.57) | HTR2CHTR2BSMN1; SMN2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | HTR7 168/4885HTR2C 190/4885HTR2B 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.